The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO GI 2023 | Overserving responses to treatment in rectal cancer with liquid biopsies
Paul Bernard Romesser, MD, Memorial Sloan Kettering Cancer Center, New York, NY, comments on the future of liquid biopsies in rectal cancer. Current research assessing the role of liquid biopsies and circulating tumor DNA have yielded promising results. However, additional studies are need to demonstrate clinical utility, and their ability to predict responses in patients. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Gastrointestinal Cancers (GI) Symposium in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
